IL187787A - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, methods for preparing same, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments - Google Patents

Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, methods for preparing same, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments

Info

Publication number: IL187787A
Authority: IL; Israel
Prior art keywords: methyl; phenyl; imidazol; benzamide; pyridin
Prior art date: 2005-07-20

Application number

IL187787A

Other languages

English (en)

Other versions

IL187787A0 (en

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-20

Filing date

2007-11-29

Publication date

2012-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-11-29 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-07 Publication of IL187787A0 publication Critical patent/IL187787A0/en

2012-07-31 Publication of IL187787A publication Critical patent/IL187787A/en

Links

150000003839 salts Chemical class 0.000 title claims description 46
238000000034 method Methods 0.000 title claims description 13
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical class C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
239000003814 drug Substances 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title claims description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
239000012458 free base Substances 0.000 claims description 26
239000007787 solid Substances 0.000 claims description 24
239000000725 suspension Substances 0.000 claims description 16
238000001816 cooling Methods 0.000 claims description 15
238000001914 filtration Methods 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
238000003756 stirring Methods 0.000 claims description 10
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
239000011541 reaction mixture Substances 0.000 claims description 6
102000001253 Protein Kinase Human genes 0.000 claims description 5
230000005764 inhibitory process Effects 0.000 claims description 5
239000012299 nitrogen atmosphere Substances 0.000 claims description 5
108060006633 protein kinase Proteins 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
239000003981 vehicle Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
238000010899 nucleation Methods 0.000 claims description 2
YCBPQSYLYYBPDW-UHFFFAOYSA-N 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrate;hydrochloride Chemical compound O.Cl.C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 YCBPQSYLYYBPDW-UHFFFAOYSA-N 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
239000000243 solution Substances 0.000 description 25
238000000634 powder X-ray diffraction Methods 0.000 description 24
-1 salt hydrates Chemical class 0.000 description 13
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000000523 sample Substances 0.000 description 11
239000002002 slurry Substances 0.000 description 10
239000002904 solvent Substances 0.000 description 10
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
230000004580 weight loss Effects 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
239000013078 crystal Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
238000002441 X-ray diffraction Methods 0.000 description 6
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000000354 decomposition reaction Methods 0.000 description 6
239000000155 melt Substances 0.000 description 6
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 5
150000007522 mineralic acids Chemical class 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000003460 sulfonic acids Chemical class 0.000 description 5
150000003467 sulfuric acid derivatives Chemical class 0.000 description 5
238000002411 thermogravimetry Methods 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
235000011007 phosphoric acid Nutrition 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 3
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229940098779 methanesulfonic acid Drugs 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
150000004682 monohydrates Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000012453 solvate Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000003556 assay Methods 0.000 description 2
229940092714 benzenesulfonic acid Drugs 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000004712 monophosphates Chemical class 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
SHTKXTVHHWDYPE-UHFFFAOYSA-N benzamide;4-methylbenzenesulfonic acid Chemical compound NC(=O)C1=CC=CC=C1.CC1=CC=C(S(O)(=O)=O)C=C1 SHTKXTVHHWDYPE-UHFFFAOYSA-N 0.000 description 1
OJCKJHHYVUPUSJ-UHFFFAOYSA-N benzamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.NC(=O)C1=CC=CC=C1 OJCKJHHYVUPUSJ-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000002336 sorption--desorption measurement Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
150000008054 sulfonate salts Chemical class 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL187787A 2005-07-20 2007-11-29 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, methods for preparing same, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments IL187787A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70140605P	2005-07-20	2005-07-20
US71621305P	2005-09-12	2005-09-12
PCT/US2006/027878 WO2007015871A1 (fr)	2005-07-20	2006-07-18	Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number	Publication Date
IL187787A0 IL187787A0 (en)	2008-08-07
IL187787A true IL187787A (en)	2012-07-31

Family

ID=37398525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL187787A IL187787A (en)	2005-07-20	2007-11-29	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, methods for preparing same, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments

Country Status (33)

Country	Link
US (4)	US8163904B2 (fr)
EP (2)	EP1910336B1 (fr)
JP (1)	JP5129132B2 (fr)
KR (3)	KR101755137B1 (fr)
CN (1)	CN102267981A (fr)
AR (1)	AR057467A1 (fr)
AT (1)	ATE514689T1 (fr)
AU (2)	AU2006276205C1 (fr)
BR (1)	BRPI0613605A2 (fr)
CA (2)	CA2615669C (fr)
CY (1)	CY1111772T1 (fr)
DK (1)	DK1910336T3 (fr)
EC (1)	ECSP088118A (fr)
ES (1)	ES2634291T3 (fr)
GT (1)	GT200600316A (fr)
HR (1)	HRP20110639T1 (fr)
IL (1)	IL187787A (fr)
JO (1)	JO2757B1 (fr)
MA (1)	MA29686B1 (fr)
MX (1)	MX2008000892A (fr)
MY (1)	MY149889A (fr)
NO (1)	NO341313B1 (fr)
NZ (2)	NZ591142A (fr)
PE (1)	PE20070241A1 (fr)
PL (1)	PL1910336T3 (fr)
PT (1)	PT1910336E (fr)
RU (4)	RU2509767C1 (fr)
SG (1)	SG170772A1 (fr)
SI (1)	SI1910336T1 (fr)
TN (1)	TNSN08028A1 (fr)
TW (1)	TWI455934B (fr)
UY (1)	UY29683A1 (fr)
WO (1)	WO2007015871A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es)	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
KR101292508B1 (ko) *	2006-04-07	2013-08-01	노파르티스 아게	백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
EP1923053A1 (fr) *	2006-09-27	2008-05-21	Novartis AG	Composition pharmaceutique comprenant de la nilotinib ou son sel
US20100016590A1 (en)	2008-07-17	2010-01-21	Teva Pharmaceutical Industries Ltd.	Nilotinib intermediates and preparation thereof
ES2394258T3 (es) *	2008-11-05	2013-01-30	Teva Pharmaceutical Industries Ltd.	Formas cristalinas de Nilotinib HCL
EP2186514B1 (fr)	2008-11-14	2016-06-29	Kinki University	Traitement de tumeurs malignes de la gaine des nerfs périphériques
CA2753637A1 (fr)	2009-03-06	2010-09-10	Novartis Ag	Utilisation de derives de pyrimidylaminobenzamide pour le traitement de troubles a mediation par une kinase contenant un leucine zipper et un motif alpha sterile (zak)
TW201102068A (en)	2009-06-02	2011-01-16	Novartis Ag	Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) *	2009-06-09	2011-03-03	Auspex Pharmaceuticals, Inc.	Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (fr)	2009-09-17	2011-03-24	Generics [Uk] Limited	Sel de dichlorhydrate de nilotinib
AU2010310705A1 (en)	2009-10-23	2012-04-19	Novartis Ag	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JO3634B1 (ar)	2009-11-17	2020-08-27	Novartis Ag	طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (fr)	2010-01-15	2011-07-21	Generics [Uk] Limited	Nouveau polymorphe de monochlorhydrate de nilotinib monohydraté
EP2558098A2 (fr)	2010-04-16	2013-02-20	Novartis AG	Traitement d'un cancer du sein résistant à l'endocrine
EP2382976A1 (fr)	2010-04-30	2011-11-02	Hiroshima University	Utilisation d'inhibiteurs pdgf-r pour le traitement de métastases dans les ganglions lymphatiques du cancer gastrique
EP2966072A3 (fr)	2010-06-21	2016-02-24	Teva Pharmaceutical Industries, Ltd.	Formes cristallines des sels nilotinib hydrobromide, succinate, glutamate, acetate, l-malate et maleate
WO2012014127A1 (fr)	2010-07-30	2012-02-02	Ranbaxy Laboratories Limited	Inhibiteurs de 5-lipoxygénase
CN102453024B (zh) *	2010-10-27	2014-09-03	浙江九洲药业股份有限公司	一种尼罗替尼盐酸盐晶型及其制备方法
IN2010CH03577A (fr) *	2010-11-26	2012-07-20	Hetero Research Foundation
AR086913A1 (es) *	2011-06-14	2014-01-29	Novartis Ag	4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
RU2014120792A (ru)	2011-10-28	2015-12-10	Новартис Аг	Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (fr)	2011-10-28	2013-05-02	Novartis Ag	Méthode de traitement des tumeurs stromales gastro-intestinales
SG11201401476TA (en)	2011-11-14	2014-10-30	Novartis Ag	Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2872142A1 (fr)	2012-07-11	2015-05-20	Novartis AG	Méthode de traitement de tumeurs stromales gastro-intestinales
US9376419B2 (en)	2012-10-15	2016-06-28	Apotex Inc.	Solid forms of nilotinib hydrochloride
AU2013333953B2 (en) *	2012-10-19	2017-08-31	Basf Se	Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2792360A1 (fr)	2013-04-18	2014-10-22	IP Gesellschaft für Management mbH	(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
JP2016522182A (ja)	2013-04-24	2016-07-28	ドクターレディズラボラトリーズリミテッド	ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) *	2013-11-28	2021-08-20	Общество с ограниченной ответственностью "Мамонт Фарм"	Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (fr)	2013-12-16	2015-06-25	Ranbaxy Laboratories Limited	Mono-oxalate de nilotinib et sa forme cristalline
WO2016020891A1 (fr)	2014-08-08	2016-02-11	Dr. Reddy’S Laboratories Limited	Procédé de préparation de formes polymorphes du nilotinib
PL3189045T3 (pl) *	2014-08-11	2022-04-04	Sun Pharmaceutical Industries Limited	Nowe sole nilotynibu i jego polimorfy
EP3271351A1 (fr)	2015-03-20	2018-01-24	Cipla Limited	Nouvelle forme polymorphe x de dichlorhydrate de nilotinib hydrate
WO2017129694A1 (fr)	2016-01-26	2017-08-03	Farma Grs, D.O.O.	Dinitrate de nilotinib (v) et formes cristallines de celui-ci
WO2017149550A1 (fr) *	2016-03-02	2017-09-08	Msn Laboratories Private Limited	Forme amorphe du 4-méthyl-n-[3-(4-méthyl-1h-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
SMT202000563T1 (it)	2016-03-14	2020-11-10	Pliva Hrvatska D O O	Forem allo stato solido di sali di nilotinib
EP3404025B1 (fr)	2017-05-16	2019-12-04	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procede de preparation de nilotinib pur et de son sel
CZ2017821A3 (cs)	2017-12-20	2019-07-03	Zentiva, K.S.	Léková forma obsahující krystalický nilotinib
TWI831259B (zh)	2018-06-15	2024-02-01	漢達生技醫藥股份有限公司	包含達沙替尼十二烷基硫酸鹽組合物的膠囊
US12065426B2 (en)	2018-11-05	2024-08-20	Laurus Labs Limited	Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
JP7211644B2 (ja)	2019-02-18	2023-01-24	スレイバック・ファーマ・エルエルシー	ニロチニブの医薬組成物
CA3168680A1 (fr)	2020-01-31	2021-08-05	Nanocopoeia, Llc	Microparticules de nilotinib amorphe et leurs utilisations
EP4103560A1 (fr) *	2020-02-15	2022-12-21	Cipla Limited	Nouveaux sels de nilotinib et formes polymorphes de celui-ci
EP4142699A1 (fr)	2020-04-30	2023-03-08	Nanocopoeia LLC	Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib
CN114133378B (zh) *	2020-09-04	2023-08-15	成都苑东生物制药股份有限公司	一种盐酸尼洛替尼共晶及其制备方法
KR20230097021A (ko)	2020-09-29	2023-06-30	선전 파마신 컴퍼니 리미티드	약학 조성물
EP4260848A1 (fr)	2022-04-11	2023-10-18	Lotus Pharmaceutical Co., Ltd.	Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation
LU103368B1 (en)	2022-12-29	2024-11-04	Renata Pharmaceuticals Ireland Ltd	Pharmaceutical suspension of nilotinib
US12419892B2 (en)	2023-11-08	2025-09-23	Xspray Pharma Ab	Pharmaceutical compositions comprising nilotinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2081108C1 (ru) *	1991-10-16	1997-06-10	Циба-Гейги АГ	Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en)	1992-08-31	1996-05-14	Ciba-Geigy Corporation	Further use of pyrimidine derivatives
AU691834B2 (en)	1993-10-01	1998-05-28	Novartis Ag	Pharmacologically active pyridine derivatives and processes for the preparation thereof
CO4940418A1 (es) *	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
MXPA02005866A (es) *	1999-12-14	2002-10-23	Nippon Shinyaku Co Ltd	Derivados de heterociclo y drogas.
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB2398565A (en) *	2003-02-18	2004-08-25	Cipla Ltd	Imatinib preparation and salts
PE20051096A1 (es) *	2004-02-04	2006-01-23	Novartis Ag	Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
SA06270147B1 (ar) *	2005-06-09	2009-12-22	نوفارتيس ايه جي	عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) *	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

2006
- 2006-07-14 GT GT200600316A patent/GT200600316A/es unknown
- 2006-07-18 CA CA2615669A patent/CA2615669C/fr active Active
- 2006-07-18 AT AT06787733T patent/ATE514689T1/de active
- 2006-07-18 MY MYPI20063405A patent/MY149889A/en unknown
- 2006-07-18 RU RU2012143989/04A patent/RU2509767C1/ru active
- 2006-07-18 KR KR1020157022022A patent/KR101755137B1/ko active Active
- 2006-07-18 KR KR1020147007695A patent/KR20140047737A/ko not_active Ceased
- 2006-07-18 RU RU2011120363/04A patent/RU2483065C2/ru active
- 2006-07-18 JP JP2008522900A patent/JP5129132B2/ja active Active
- 2006-07-18 WO PCT/US2006/027878 patent/WO2007015871A1/fr not_active Ceased
- 2006-07-18 US US11/995,898 patent/US8163904B2/en active Active
- 2006-07-18 ES ES10150322.5T patent/ES2634291T3/es active Active
- 2006-07-18 AU AU2006276205A patent/AU2006276205C1/en active Active
- 2006-07-18 DK DK06787733.2T patent/DK1910336T3/da active
- 2006-07-18 PL PL06787733T patent/PL1910336T3/pl unknown
- 2006-07-18 SI SI200631100T patent/SI1910336T1/sl unknown
- 2006-07-18 EP EP06787733A patent/EP1910336B1/fr active Active
- 2006-07-18 SG SG201102150-8A patent/SG170772A1/en unknown
- 2006-07-18 EP EP10150322.5A patent/EP2186808B1/fr active Active
- 2006-07-18 AR ARP060103071A patent/AR057467A1/es unknown
- 2006-07-18 KR KR1020087001461A patent/KR20080027855A/ko not_active Ceased
- 2006-07-18 CN CN2011102503529A patent/CN102267981A/zh active Pending
- 2006-07-18 RU RU2008105827/04A patent/RU2434864C2/ru active
- 2006-07-18 MX MX2008000892A patent/MX2008000892A/es active IP Right Grant
- 2006-07-18 NZ NZ591142A patent/NZ591142A/xx unknown
- 2006-07-18 CA CA2823946A patent/CA2823946C/fr active Active
- 2006-07-18 NZ NZ564182A patent/NZ564182A/en unknown
- 2006-07-18 PT PT06787733T patent/PT1910336E/pt unknown
- 2006-07-18 BR BRPI0613605-2A patent/BRPI0613605A2/pt not_active Application Discontinuation
- 2006-07-18 HR HR20110639T patent/HRP20110639T1/hr unknown
- 2006-07-19 TW TW095126416A patent/TWI455934B/zh active
- 2006-07-20 PE PE2006000874A patent/PE20070241A1/es active IP Right Grant
- 2006-07-20 UY UY29683A patent/UY29683A1/es not_active Application Discontinuation
- 2006-07-20 JO JO2006242A patent/JO2757B1/en active
2007
- 2007-11-29 IL IL187787A patent/IL187787A/en active IP Right Grant
2008
- 2008-01-09 MA MA30563A patent/MA29686B1/fr unknown
- 2008-01-18 EC EC2008008118A patent/ECSP088118A/es unknown
- 2008-01-18 TN TNP2008000028A patent/TNSN08028A1/en unknown
- 2008-02-20 NO NO20080897A patent/NO341313B1/no unknown
2010
- 2010-11-12 AU AU2010241419A patent/AU2010241419C1/en active Active
2011
- 2011-08-26 CY CY20111100813T patent/CY1111772T1/el unknown
2012
- 2012-03-13 US US13/419,132 patent/US8389537B2/en active Active
2013
- 2013-01-15 RU RU2013101749/04A patent/RU2605551C2/ru active
- 2013-01-22 US US13/747,052 patent/US8580806B2/en active Active
- 2013-10-11 US US14/051,725 patent/US9163005B2/en active Active

Also Published As

Publication number	Publication date
PL1910336T3 (pl)	2011-11-30
EP1910336B1 (fr)	2011-06-29
KR20140047737A (ko)	2014-04-22
AR057467A1 (es)	2007-12-05
HRP20110639T1 (hr)	2011-10-31
TNSN08028A1 (en)	2009-07-14
US8389537B2 (en)	2013-03-05
CY1111772T1 (el)	2015-10-07
CA2615669C (fr)	2013-11-12
RU2434864C2 (ru)	2011-11-27
RU2605551C2 (ru)	2016-12-20
MY149889A (en)	2013-10-31
US20140038994A1 (en)	2014-02-06
US8163904B2 (en)	2012-04-24
NO341313B1 (no)	2017-10-09
PT1910336E (pt)	2011-09-05
KR20080027855A (ko)	2008-03-28
HK1116778A1 (en)	2009-01-02
EP2186808A1 (fr)	2010-05-19
GT200600316A (es)	2007-04-02
CA2823946C (fr)	2015-12-29
ATE514689T1 (de)	2011-07-15
RU2483065C2 (ru)	2013-05-27
TWI455934B (zh)	2014-10-11
AU2010241419B2 (en)	2012-03-29
ECSP088118A (es)	2008-02-20
AU2010241419A1 (en)	2010-12-02
US20080200487A1 (en)	2008-08-21
EP2186808B1 (fr)	2017-04-19
DK1910336T3 (da)	2011-10-03
CN102267981A (zh)	2011-12-07
MA29686B1 (fr)	2008-08-01
MX2008000892A (es)	2008-03-18
BRPI0613605A2 (pt)	2011-01-18
NZ591142A (en)	2012-09-28
EP1910336A1 (fr)	2008-04-16
US20120270891A1 (en)	2012-10-25
US20130137712A1 (en)	2013-05-30
ES2634291T3 (es)	2017-09-27
RU2011120363A (ru)	2012-11-27
US9163005B2 (en)	2015-10-20
AU2006276205C1 (en)	2024-08-01
IL187787A0 (en)	2008-08-07
RU2509767C1 (ru)	2014-03-20
US8580806B2 (en)	2013-11-12
NO20080897L (no)	2008-02-20
TW200800950A (en)	2008-01-01
AU2010241419C1 (en)	2024-05-23
AU2006276205B2 (en)	2010-08-19
AU2006276205A1 (en)	2007-02-08
RU2008105827A (ru)	2009-08-27
PE20070241A1 (es)	2007-03-22
SI1910336T1 (sl)	2011-10-28
JO2757B1 (en)	2014-03-15
UY29683A1 (es)	2007-02-28
WO2007015871A1 (fr)	2007-02-08
CA2615669A1 (fr)	2007-02-08
RU2013101749A (ru)	2014-07-27
KR101755137B1 (ko)	2017-07-06
SG170772A1 (en)	2011-05-30
JP5129132B2 (ja)	2013-01-23
NZ564182A (en)	2011-03-31
CA2823946A1 (fr)	2007-02-08
KR20150100946A (ko)	2015-09-02
JP2009502796A (ja)	2009-01-29

Publication	Publication Date	Title
IL187787A (en)	2012-07-31	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, methods for preparing same, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
AU2012201453C1 (en)	2024-05-23	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
CN101228151B (zh)	2013-01-09	4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐
AU2012203844B2 (en)	2014-12-11	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
HK1143358A (en)	2010-12-31	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
HK1143358B (en)	2018-01-19	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
HK1116778B (en)	2011-12-16	Monohydrochloride monohydrate salt of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Legal Events

Date	Code	Title
2012-11-29	FF	Patent granted
2013-02-03	KB	Patent renewed
2016-06-30	KB	Patent renewed
2020-07-30	KB	Patent renewed